share_log

Femasys | 8-K/A: Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys | 8-K/A: Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Femasys | 8-K/A：Femasys公佈截至2024年9月30日的季度財務業績，並提供公司最新情況
美股SEC公告 ·  2024/11/12 22:05

Moomoo AI 已提取核心訊息

Femasys reported strong Q3 2024 results with sales increasing 127.1% YoY to $554,908, primarily driven by initial FemaSeed and FemVue sales. The company achieved significant commercial milestones, including partnerships with Boston IVF and strategic distribution agreements in Spain expected to generate over $1.3 million in the next year.Research and development expenses rose 11.1% YoY to $2.3 million, while net loss widened to $5.4 million ($0.24 per share) compared to $4.0 million ($0.26 per share) in Q3 2023. The company maintained $7.6 million in cash and cash equivalents as of September 30, 2024, expected to fund operations into July 2025.Notable achievements include receiving FDA 510(k) clearance for FemChec, CE Mark certification for FemVue MINI, and a new U.S. patent for FemBloc. The company successfully launched FemaSeed commercialization in both U.S. and European markets, with additional sales expected in Q4 2024.
Femasys reported strong Q3 2024 results with sales increasing 127.1% YoY to $554,908, primarily driven by initial FemaSeed and FemVue sales. The company achieved significant commercial milestones, including partnerships with Boston IVF and strategic distribution agreements in Spain expected to generate over $1.3 million in the next year.Research and development expenses rose 11.1% YoY to $2.3 million, while net loss widened to $5.4 million ($0.24 per share) compared to $4.0 million ($0.26 per share) in Q3 2023. The company maintained $7.6 million in cash and cash equivalents as of September 30, 2024, expected to fund operations into July 2025.Notable achievements include receiving FDA 510(k) clearance for FemChec, CE Mark certification for FemVue MINI, and a new U.S. patent for FemBloc. The company successfully launched FemaSeed commercialization in both U.S. and European markets, with additional sales expected in Q4 2024.
Femasys公佈了強勁的2024年第三季度業績，銷售額同比增長127.1%，達到554,908美元，這主要得益於初步的FemaSeed和FemVue銷售。公司實現了顯著的商業里程碑，包括與Boston IVF的合作以及在西班牙的戰略分銷協議，預計在下一年將產生超過130萬美元的收入。研發支出同比增長11.1%，達到230萬美元，而淨虧損擴大至540萬美元（每股0.24美元），相比之下，2023年第三季度爲400萬美元（每股0.26美元）。截至2024年9月30日，公司保持了760萬美元的現金及現金等價物，預計可資助運營至2025年7月。值得注意的成就包括獲得FDA 510(k)批准的FemChec、FemVue MINI的CE標誌認證，以及FemBloc的新美國專利。公司成功在美國和歐洲市場啓動了FemaSeed的商業化，預計在2024年第四季度將有更多銷售。
Femasys公佈了強勁的2024年第三季度業績，銷售額同比增長127.1%，達到554,908美元，這主要得益於初步的FemaSeed和FemVue銷售。公司實現了顯著的商業里程碑，包括與Boston IVF的合作以及在西班牙的戰略分銷協議，預計在下一年將產生超過130萬美元的收入。研發支出同比增長11.1%，達到230萬美元，而淨虧損擴大至540萬美元（每股0.24美元），相比之下，2023年第三季度爲400萬美元（每股0.26美元）。截至2024年9月30日，公司保持了760萬美元的現金及現金等價物，預計可資助運營至2025年7月。值得注意的成就包括獲得FDA 510(k)批准的FemChec、FemVue MINI的CE標誌認證，以及FemBloc的新美國專利。公司成功在美國和歐洲市場啓動了FemaSeed的商業化，預計在2024年第四季度將有更多銷售。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間